Tatva Chintan Pharma Chem Limited
All news and filings related to Tatva Chintan Pharma Chem Limited.
View all news & filings- Low impact
Tatva Chintan to Meet HSBC Securities on Sep 15
Tatva Chintan Pharma Chem Limited will hold a one-to-one virtual meeting with HSBC Securities and Capital Pvt. Ltd. on September 15, 2026. No unpublished price-sensitive information will be shared.
Read the summary - Medium impact
Tatva Chintan Pharma Chem's Credit Rating Upgraded by CRISIL to A-/Stable
CRISIL Ratings has upgraded Tatva Chintan Pharma Chem Limited's credit rating to CRISIL A-/Stable for long-term facilities and CRISIL A2+ for short-term facilities. The total rated bank facilities amount to ₹245 Crore. The upgrade reflects improved financial stability.
Read the summary - Low impact
Tatva Chintan Pharma Chem Announces 30th AGM on September 25, 2026
Tatva Chintan Pharma Chem Limited will hold its 30th Annual General Meeting on September 25, 2026, at 4:00 PM IST via VC/OAVM. Newspaper advertisements were published on August 28, 2026, detailing the AGM notice, record date, book closure, and e-voting information.
Read the summary - Low impact
Tatva Chintan Sets Record Date for AGM and Dividend on Sept 11, 2026
Tatva Chintan Pharma Chem Limited has set Friday, September 11, 2026, as the record date for its final dividend for FY2025-26. The 30th AGM is scheduled for September 25, 2026, with dividend payment on or after October 1, 2026. September 18, 2026, is the e-voting cut-off date.
Read the summary - Low impact
Tatva Chintan Pharma Chem Limited Submits BRSR Report for FY 2025-26
Tatva Chintan Pharma Chem Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. The report details the company's ESG initiatives and forms part of the Annual Report. It is available on the company's website.
Read the summary - Medium impact
Tatva Chintan Pharma Chem Announces 30th AGM on Sep 25, 2026; Key Re-appointments & Dividend Approval
Tatva Chintan Pharma Chem will hold its 30th AGM on September 25, 2026, via VC/OAVM. The agenda includes adopting FY26 financial statements, declaring dividends, and re-appointing key management personnel, including the Managing Director, for three-year terms starting February 1, 2027. The company also seeks approval to raise borrowing limits to ₹1,000 crore.
Read the summary - Low impact
Tatva Chintan Pharma Chem Ltd: Ajay Rawat Resigns as AVP - R&D
Mr. Ajay Rawat, Assistant Vice President – Research and Development at Tatva Chintan Pharma Chem Limited, has resigned. His resignation was accepted on August 19, 2026, and will be effective from November 13, 2026. The company has filed the necessary disclosures.
Read the summary - Low impact
Tatva Chintan Pharma Chem Limited announces 30th AGM on September 25, 2026, via VC/OAVM.
Tatva Chintan Pharma Chem Limited will hold its 30th Annual General Meeting (AGM) on September 25, 2026, at 4:00 PM IST. The meeting will be conducted virtually via Video Conferencing/Other Audio Visual Means. This is a regulatory filing for the AGM notice.
Read the summary - Low impact
Tatva Chintan Pharma Chem: Final Dividend for FY26 & TDS Intimation
Tatva Chintan Pharma Chem recommended a final dividend of ₹2.00 per share for FY 2025-26. The company has issued detailed guidelines on Tax Deduction at Source (TDS) for resident and non-resident shareholders. Shareholders must submit necessary documentation by September 10, 2026, to ensure correct tax withholding or claim exemptions.
Read the summary - Low impact
Tatva Chintan Pharma Chem Schedules Analyst/Investor Meetings on Aug 12
Tatva Chintan Pharma Chem Limited will participate in investor meetings on August 12, 2026. The company will hold virtual one-on-one meetings with Ambit Global Private Client and TA Associate. Publicly available information will be used, and no UPSI will be shared.
Read the summary - Low impact
Tatva Chintan Pharma Chem Schedules Investor Meetings on August 12, 2026
Tatva Chintan Pharma Chem Limited will participate in investor meetings on August 12, 2026. The company will hold one-to-one virtual meetings with Ambit Global Private Client and TA Associate. Discussions will be based on publicly available information.
Read the summary - Low impact
Tatva Chintan Pharma Chem Schedules Investor Meeting on Aug 6
Tatva Chintan Pharma Chem Limited will hold a virtual one-to-one meeting with Mahindra Manulife Investment Management Private Limited on August 6, 2026. The company will discuss publicly available information.
Read the summary - Low impact
Tatva Chintan Pharma Chem to participate in One-to-One Virtual Meeting with ChrysCapital on Aug 6, 2026
Tatva Chintan Pharma Chem Limited will participate in a virtual one-to-one meeting with ChrysCapital Associates LLP on August 06, 2026. No unpublished price-sensitive information will be disclosed during the meeting.
Read the summary - Low impact
Tatva Chintan Pharma Chem Schedules Investor Meet on July 31, 2026
Tatva Chintan Pharma Chem Limited will participate in a one-to-one virtual investor meeting with Motilal Oswal AMC on July 31, 2026. No unpublished price sensitive information will be shared.
Read the summary - Low impact
Tatva Chintan to Participate in Investor Meeting with Ventura Securities on July 30
Tatva Chintan Pharma Chem Limited will participate in a one-to-one virtual meeting with Ventura Securities on July 30, 2026. The company will only discuss publicly available information.
Read the summary - Low impact
Tatva Chintan Pharma Chem to Meet Tamohara Investment Managers on July 30
Tatva Chintan Pharma Chem Limited will hold a one-to-one virtual meeting with Tamohara Investment Managers Pvt. Ltd. on July 30, 2026. No unpublished price-sensitive information will be shared.
Read the summary - Low impact
Tatva Chintan Pharma Chem to Meet Alchemy Capital Management on July 28
Tatva Chintan Pharma Chem Limited will participate in a virtual one-on-one meeting with Alchemy Capital Management Pvt. Ltd. on July 28, 2026. The company will only discuss publicly available information.
Read the summary - High impact
Tatva Chintan Q1 FY27 Earnings Call Transcript Released
Tatva Chintan reported Q1 FY27 revenue of INR 1,671 million (up 43% YoY) and EBITDA of INR 323 million (up 86% YoY). The company approved a INR 200 crore greenfield manufacturing facility. Key segments like PTC, PASC, and SDA showed strong year-on-year growth. A significant milestone was the qualification of a semiconductor industry product.
Read the summary - Low impact
Tatva Chintan to Participate in Investor Group Meeting Hosted by ULJK Financial Services on July 27
Tatva Chintan Pharma Chem Limited will participate in a virtual group meeting hosted by ULJK Financial Services on July 27, 2026. The company will only discuss publicly available information.
Read the summary - Medium impact
Tatva Chintan Pharma Chem Limited Holds Groundbreaking Ceremony for New Greenfield Unit
Tatva Chintan Pharma Chem Limited held a groundbreaking ceremony on July 20, 2026, for its new greenfield manufacturing unit in Dahej, Gujarat. This expansion is part of the company's growth strategy to meet increasing market demands.
Read the summary - Low impact
Tatva Chintan Pharma Chem Publishes Financial Results Extract in Newspapers
Tatva Chintan Pharma Chem Limited published financial results for the quarter ended June 30, 2026. The results were published in Financial Express and Vadodara Samachar on July 18, 2026, and are also available on the company's website.
Read the summary - Low impact
Tatva Chintan Pharma Chem Limited Shares Earnings Call Recording Link
Tatva Chintan Pharma Chem Limited has made the recording of its earnings call held on July 17, 2026, available on its website. Investors can access the audio recording via the link provided in the announcement.
Read the summary - High impact
Tatva Chintan Pharma Chem Q1FY27 Results: Revenue Up 43% to ₹1,671 Mn, PAT Jumps 140%
Tatva Chintan Pharma Chem reported Q1FY27 results with revenue from operations at ₹1,671 Mn, a 43% YoY increase. PAT surged 140% to ₹160 Mn. EBITDA grew 86% to ₹323 Mn. The company highlighted strong performance across its product segments, including PTC, SDA, ESS, and PASC.
Read the summary - High impact
Tatva Chintan Board Approves Q1 Results, Reappoints Directors, Expands Capacity
Tatva Chintan Pharma Chem Limited reported its Q1 FY27 results. The Board approved re-appointments of its MD and Whole-time Directors for three years from Feb 2027. The company will invest ₹200 crore in capacity expansion at Dahej, Gujarat, to be completed in 21 months. Borrowing limits increased to ₹1,000 crore.
Read the summary - High impact
Tatva Chintan Approves Q1 FY27 Results, Re-appoints Directors, and Plans Capacity Expansion
Tatva Chintan announced Q1 FY27 results with consolidated profit after tax at ₹159.81 million. The company re-appointed Mr. Chintan Nitinkumar Shah, Mr. Ajaykumar Mansukhlal Patel, and Mr. Shekhar Rasiklal Somani as directors for three years from Feb 2027. A capacity expansion of ₹200 crore at Dahej is planned.
Read the summary - High impact
Tatva Chintan Pharma Chem Approves Q1 FY27 Results, Reappoints Directors, Expands Capacity
Tatva Chintan Pharma Chem approved Q1 FY27 results on July 17, 2026. The Board re-appointed Mr. Chintan Shah as MD and Messrs. Patel and Somani as Whole-time Directors for three years from Feb 1, 2027. The company will invest ₹200 crore for capacity expansion at Dahej, adding 344 KL reactor capacity over 21 months. Borrowing limits increased to ₹1,000 crore.
Read the summary - Low impact
Tatva Chintan Pharma Chem Ltd. Files SEBI Compliance Certificate for Q1 FY27
Tatva Chintan Pharma Chem Limited submitted a compliance certificate for the quarter ended June 30, 2026, as per SEBI regulations. The certificate was received from its Registrar and Share Transfer Agent, MUFG Intime India Private Limited.
Read the summary - Low impact
Tatva Chintan Pharma Chem Ltd: Trading Window Closed for Q1 FY27 Results
Tatva Chintan Pharma Chem Ltd has closed its trading window from July 1, 2026, until 48 hours after the declaration of Q1 FY27 financial results. This is to comply with SEBI insider trading regulations.
Read the summary - Low impact
Tatva Chintan Pharma Chem to Meet Valcore Capital Advisors on June 17
Tatva Chintan Pharma Chem Limited will hold a virtual one-on-one meeting with Valcore Capital Advisors on June 17, 2026. The company will discuss publicly available information.
Read the summary - Low impact
Tatva Chintan Promoters Declare No Share Encumbrance for FY26
Tatva Chintan Pharma Chem Limited promoters and concert parties declare no share encumbrance for the financial year ending March 31, 2026. This disclosure is made under SEBI Takeover Regulations.
Read the summary - Low impact
Tatva Chintan Pharma Chem: Promoter Declaration on Non-Encumbrance of Shares for FY26
Tatva Chintan Pharma Chem announced on 19 May 2026, that the promoter group, including Ajay Mansukhlal Patel, declared no encumbrance of shares for the financial year ended 31 March 2026. The declaration complies with Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Read the summary - High impact
Tatva Chintan Pharma Chem Q4 FY26 Earnings Call Transcript Released
Tatva Chintan Pharma Chem released its Q4 FY26 earnings call transcript. The company reported Q4 FY26 revenue of INR1,341 million, up 24% YoY, and EBITDA of INR281 million, up 214% YoY. Electrolyte Salts revenue surged 1,378% YoY. The company reaffirmed FY27 revenue growth guidance of 25% and EBITDA margins of 20-22%. The Jolva project is slated for commercialization in early 2028.
Read the summary - Low impact
Tatva Chintan Pharma Chem Limited Publishes Financial Results Extract in Newspapers
Tatva Chintan Pharma Chem Limited published its financial results extract for the quarter and financial year ended March 31, 2026. The publication appeared in the Financial Express and Vadodara Samachar on May 17, 2026, adhering to SEBI regulations. The results are also available on the company's website.
Read the summary - Low impact
Tatva Chintan Pharma Chem Limited: Earnings Call Recording Available Online
Tatva Chintan Pharma Chem Limited has made the recording of its earnings call, held on May 16, 2026, available on its website. The recording can be accessed via a direct link provided by the company.
Read the summary - High impact
Tatva Chintan Pharma Chem Ltd. Presents Investor Presentation for Q4FY26 & FY26
Tatva Chintan Pharma Chem Ltd. reported a 32% YoY increase in FY26 revenue to ₹5,059 million and a 636% surge in PAT to ₹421 million. Q4FY26 revenue grew 24% YoY to ₹1,341 million, with PAT rising 902% to ₹103 million. The company's EBITDA margin improved significantly in both FY26 and Q4FY26.
Read the summary - Medium impact
Tatva Chintan Pharma Chem Ltd. Board Approves Final Dividend and Appoints Auditors
Tatva Chintan Pharma Chem Limited's Board approved audited financial results for FY26 ending March 31, 2026. A final dividend of ₹2 per share was recommended. The company also appointed M/s. Zarna Thakar & Associates as Cost Auditor and RSM Astute Consultech Private Limited as Internal Auditor for FY27.
Read the summary - Medium impact
Tatva Chintan Pharma Chem Recommends Final Dividend of ₹2/Share for FY26
Tatva Chintan Pharma Chem Limited's Board approved audited financial results for FY26. They recommended a final dividend of ₹2 per share for FY26, subject to shareholder approval at the AGM. The company also appointed M/s. Zarna Thakar & Associates as Cost Auditor and RSM Astute Consultech Private Limited as Internal Auditor for FY27.
Read the summary - Medium impact
Tatva Chintan Pharma Chem Approves FY26 Audited Results and Recommends Final Dividend
Tatva Chintan Pharma Chem Limited's Board approved audited financial results for FY26. A final dividend of ₹2 per share was recommended, subject to shareholder approval at the AGM. M/s. Zarna Thakar & Associates appointed as Cost Auditor and RSM Astute Consultech Private Limited as Internal Auditor for FY27.
Read the summary - Low impact
Tatva Chintan Pharma Chem Schedules Q4FY26 Earnings Call for May 16, 2026
Tatva Chintan Pharma Chem Limited will host its Q4FY26 earnings call on Saturday, May 16, 2026, at 05:00 PM IST. The call will discuss financial results for the quarter and fiscal year ended March 31, 2026. Management representatives will be present.
Read the summary - Low impact
Tatva Chintan Pharma Chem Files Compliance Certificate for Q4 FY26
Tatva Chintan Pharma Chem Limited submitted a compliance certificate for the quarter ended March 31, 2026, as per SEBI regulations. The certificate was provided by their Registrar and Share Transfer Agent, MUFG Intime India Private Limited. The information confirms proper processing of dematerialised securities.
Read the summary - Low impact
Tatva Chintan Pharma Chem to Close Trading Window from April 1, 2026
Tatva Chintan Pharma Chem Limited will close its trading window from April 1, 2026. The window will reopen 48 hours after the declaration of audited financial results for the quarter and financial year ending March 31, 2026.
Read the summary - Low impact
Tatva Chintan Pharma Chem to Meet OysterRock Capital on March 24, 2026
Tatva Chintan Pharma Chem Limited will participate in a one-on-one virtual meeting with OysterRock Capital on March 24, 2026. The company will only share publicly available information.
Read the summary - Medium impact
Tatva Chintan Faces Natural Gas Supply Cuts & Price Hikes Due to New Govt Order
Tatva Chintan will receive only 80% of its average natural gas supply due to a new government order regulating allocation and pricing. The company is exploring alternative fuels and process optimizations to manage the impact, though the financial implications are not yet fully quantifiable.
Read the summary - Low impact
Tatva Chintan Pharma Chem Limited to Participate in Investor Meeting on March 18, 2026
Tatva Chintan Pharma Chem Limited will participate in a one-on-one virtual investor meeting with Emerge Capital on March 18, 2026. Publicly available information will be discussed, and no UPSI will be shared.
Read the summary - Low impact
Tatva Chintan to Meet AskWealth Advisor on March 16
Tatva Chintan Pharma Chem Limited will participate in a one-on-one virtual investor meeting with AskWealth Advisor Private Limited on March 16, 2026. No unpublished price-sensitive information will be shared.
Read the summary - Low impact
Tatva Chintan Pharma Chem: Promoter Group Inter-se Share Transfer of 7.15 Lakh Shares
Tatva Chintan Pharma Chem Limited reported an inter-se transfer of 7,15,345 equity shares among promoters on February 6, 2026. The transaction, part of the dissolution of Ajay Mansukhlal Patel (HUF), is exempt from open offer requirements under SEBI Takeover Regulations. Promoter group shareholding remains unchanged.
Read the summary - Medium impact
Tatva Chintan Acquires 10.99% Stake in AMPIN C&I Power for ₹4 Crore
Tatva Chintan Pharma Chem Limited will acquire 10.99% equity in AMPIN C&I Power Twenty Six Private Limited for ₹4 crore. The SPV will establish a 9.9 MW solar and 9.9 MW wind power plant in Gujarat to supply green energy to Tatva Chintan, aiming to reduce energy costs.
Read the summary - Low impact
Tatva Chintan Pharma Chem to Meet ABN Capital Asset Managers on Feb 16
Tatva Chintan Pharma Chem Limited will participate in a one-on-one virtual investor meeting with ABN Capital Asset Managers LLP on February 16, 2026. The company will discuss publicly available information.
Read the summary - Low impact
Tatva Chintan Pharma Chem Files Insider Trading Report for Transactions
Tatva Chintan Pharma Chem Limited has filed a report concerning insider trading regulations. The filing includes information received from both the seller and purchaser as mandated by SEBI.
Read the summary - Low impact
Tatva Chintan Pharma Chem Ltd: Promoter to Acquire 7.15 Lakh Shares
Promoter Ajay Mansukhlal Patel will acquire 7,15,345 equity shares of Tatva Chintan Pharma Chem Limited on or after February 6, 2026. The transfer is part of the dissolution and partition of Ajay Mansukhlal Patel (HUF). Patel's stake will rise to 20.16%.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio